Seeking AlphaPfizer bid to expand Talzenna label in prostate cancer rejected by FDA4 days agoBy Dulan LokuwithanaMore
geneonline.comFDA Advisory Panel Rejects Expanded Use of Pfizer’s Talzenna for Prostate Cancer as AI Gains Traction in Improving Clinical Trial Diversity5 days agoMore
Urology TimesFDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC14 hours agoMore
Targeted OncologyFDA Approves Label Update But Not Expansion for Talazoparib/Enzalutamide in mCRPC13 hours agoBy Jordyn SavaMore
geneonline.comFDA Advisors Reject Pfizer’s Bid to Broaden Talzenna Use as AI Explored for Clinical Trial DiversityMay 23More
marketscreener.comPfizer : Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer5 days agoMore
geneonline.comFDA Panel Rejects Pfizer’s Bid to Expand Talzenna Use as AI Explored for Enhancing Clinical Trial Diversity2 days agoMore
geneonline.comFDA Panel Rejects Expanded Use of Pfizer’s Talzenna for Prostate Cancer as AI Explored to Improve Clinical Trial Diversity6 days agoMore
geneonline.comFDA Panel Rejects Expanded Use of Pfizer’s Talzenna for Prostate Cancer as AI Gains Attention in Clinical Trial Diversity4 days agoMore
Full CoverageFull Coverage